Nodal staging of high-risk cutaneous squamous cell carcinoma

High Risk Squamous Cell Carcinoma Workgroup, Dermatologic Surgery Section of the Association of Professors of Dermatology

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. Objective: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. Methods: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. Results: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. Limitations: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. Conclusion: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.

Original languageEnglish (US)
Pages (from-to)548-557
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume81
Issue number2
DOIs
StatePublished - Aug 2019

Fingerprint

Squamous Cell Carcinoma
Skin
Sentinel Lymph Node Biopsy
Peer Review
PubMed
Early Diagnosis
Ultrasonography
Neck
Head
Tomography
Magnetic Resonance Imaging
Guidelines
Survival
Neoplasms

Keywords

  • nodal staging
  • sentinel lymph node biopsy
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Dermatology

Cite this

High Risk Squamous Cell Carcinoma Workgroup, & Dermatologic Surgery Section of the Association of Professors of Dermatology (2019). Nodal staging of high-risk cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 81(2), 548-557. https://doi.org/10.1016/j.jaad.2018.09.006

Nodal staging of high-risk cutaneous squamous cell carcinoma. / High Risk Squamous Cell Carcinoma Workgroup; Dermatologic Surgery Section of the Association of Professors of Dermatology.

In: Journal of the American Academy of Dermatology, Vol. 81, No. 2, 08.2019, p. 548-557.

Research output: Contribution to journalReview article

High Risk Squamous Cell Carcinoma Workgroup & Dermatologic Surgery Section of the Association of Professors of Dermatology 2019, 'Nodal staging of high-risk cutaneous squamous cell carcinoma', Journal of the American Academy of Dermatology, vol. 81, no. 2, pp. 548-557. https://doi.org/10.1016/j.jaad.2018.09.006
High Risk Squamous Cell Carcinoma Workgroup, Dermatologic Surgery Section of the Association of Professors of Dermatology. Nodal staging of high-risk cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. 2019 Aug;81(2):548-557. https://doi.org/10.1016/j.jaad.2018.09.006
High Risk Squamous Cell Carcinoma Workgroup ; Dermatologic Surgery Section of the Association of Professors of Dermatology. / Nodal staging of high-risk cutaneous squamous cell carcinoma. In: Journal of the American Academy of Dermatology. 2019 ; Vol. 81, No. 2. pp. 548-557.
@article{0b633ea682604c80adabd2c54bc3899c,
title = "Nodal staging of high-risk cutaneous squamous cell carcinoma",
abstract = "Background: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. Objective: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. Methods: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. Results: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. Limitations: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. Conclusion: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.",
keywords = "nodal staging, sentinel lymph node biopsy, squamous cell carcinoma",
author = "{High Risk Squamous Cell Carcinoma Workgroup} and {Dermatologic Surgery Section of the Association of Professors of Dermatology} and Matthew Fox and Marc Brown and Nicholas Golda and Dori Goldberg and Christopher Miller and Melissa Pugliano-Mauro and Chrysalyne Schmults and Thuzar Shin and Thomas Stasko and Xu, {Yaohui G.} and Kishwer Nehal",
year = "2019",
month = "8",
doi = "10.1016/j.jaad.2018.09.006",
language = "English (US)",
volume = "81",
pages = "548--557",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Nodal staging of high-risk cutaneous squamous cell carcinoma

AU - High Risk Squamous Cell Carcinoma Workgroup

AU - Dermatologic Surgery Section of the Association of Professors of Dermatology

AU - Fox, Matthew

AU - Brown, Marc

AU - Golda, Nicholas

AU - Goldberg, Dori

AU - Miller, Christopher

AU - Pugliano-Mauro, Melissa

AU - Schmults, Chrysalyne

AU - Shin, Thuzar

AU - Stasko, Thomas

AU - Xu, Yaohui G.

AU - Nehal, Kishwer

PY - 2019/8

Y1 - 2019/8

N2 - Background: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. Objective: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. Methods: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. Results: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. Limitations: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. Conclusion: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.

AB - Background: While progress has been made in defining the clinical and histopathologic features of high-risk cutaneous squamous cell carcinoma (HRcSCC), optimal staging guidelines remain elusive. Objective: We seek to guide clinical practice regarding nodal staging options for patients with HRcSCC via review of evolving definitions of HRcSCC, nodal staging options, and how nodal staging may impact treatment and affect outcomes. Methods: This was a retrospective review of the published peer-reviewed literature regarding risk stratification, nodal staging, and treatment and outcomes for patients with HRcSCC via PubMed. Results: For patients without clinical lymphadenopathy, based on literature from head and neck SCC, preoperative nodal staging with ultrasonography may be more useful than computed tomography or magnetic resonance imaging. Early nodal disease is usually curable, and therefore obtaining a sentinel lymph node biopsy specimen may be considered in those with negative imaging while we await studies of nodal staging outcomes. Limitations: More data are needed to validate the relationships between primary tumor stage and sentinel lymph node biopsy status and to determine if early detection of nodal disease impacts survival for patients with HRcSCC. Conclusion: It is reasonable to consider nodal staging for patients with HRcSCC (Brigham and Women's Hospital stage T2b and T3) in the absence of clinically palpable lymphadenopathy via radiographic imaging and, if negative, sentinel lymph node biopsy.

KW - nodal staging

KW - sentinel lymph node biopsy

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85060989169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060989169&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.09.006

DO - 10.1016/j.jaad.2018.09.006

M3 - Review article

C2 - 30227190

AN - SCOPUS:85060989169

VL - 81

SP - 548

EP - 557

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -